Company to Present Corporate Update During
Investor Conference, Sept. 14,
2022, at 9:00am ET
RADNOR,
Pa., Sept. 8, 2022 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage
biopharmaceutical company, today announced its Chief Executive
Officer, Stephen Willard, and other
executive leaders will be presenting an update to the company's
business at the H.C. Wainwright & Co. 24th Annual
Global Investment Conference.
Stephen
Willard & NRXP Executives to Present Business Update at
H.C. Wainwright & Co. 24th Annual Investor Conference
Webcast Presentation Details:
Event: H.C. Wainwright 24th Annual
Global Investment Conference
Date: Wednesday, September 14, 2022
Time: 9:00 a.m. Eastern Time
Link to register for the NRx Pharmaceuticals' presentation at
the conference:
CLICK HERE. (A replay
will be available on the NRx Pharmaceuticals website for thirty
(30) days following the presentation
at www.nrxpharma.com).
About NRX-101
Up to 50% of individuals with bipolar disorder attempt suicide
over their lifetime, and estimates indicate that up to 20% may
succumb to suicide. The only FDA-approved treatment for patients
with bipolar depression and acute suicidal ideation & behavior
(ASIB) remains electroconvulsive therapy (ECT). Conventional
antidepressants can increase the risk of suicide in certain
patients; hence their labels contain a warning to that effect.
NRX-101 is a patented, fixed dose combination of D-cycloserine and
lurasidone, neither of which has shown addiction potential. Based
on the results of a Phase II study, NRX-101 received Breakthrough
Therapy designation (BTD) from the FDA for the Treatment of
Severe Bipolar Depression in Patients with ASIB after initial
stabilization with ketamine or other effective therapy.
NRX-101 is one of the first oral antidepressants currently in
late-stage clinical studies targeting the NMDA-receptor in the
brain, which represents potentially a key new mechanism to treat
depression with and without suicidality, as well as PTSD and other
indications. To date, NRX-101 is the only oral NMDA investigational
medicine focused on bipolar depression in patients with acute and
sub-acute suicidality.
NRx Pharmaceuticals expects to begin its registration trial for
NRX-101 under a SPA in 4Q 2022.
About NRx
Pharmaceuticals
NRx Pharmaceuticals, Inc. draws upon decades of collective,
scientific, and drug-development experience applying innovative
science to known molecules to address very high unmet needs and
bring improved health to patients. NRx Pharmaceuticals is led by
executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major
investment banking institutions.
Cautionary Note Regarding
Forward-Looking Statements
This announcement of NRx Pharmaceuticals, Inc. includes
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995, which may include, but are not limited to, statements
regarding our financial outlook, product development, business
prospects, and market and industry trends and conditions, as well
as the Company's strategies, plans, objectives, and goals. These
forward-looking statements are based on current beliefs,
expectations, estimates, forecasts, and projections of, as well as
assumptions made by, and information currently available to, the
Company's management.
The Company assumes no obligation to revise any forward-looking
statement, whether as a result of new information, future events or
otherwise. Accordingly, you should not place reliance on any
forward-looking statement, and all forward-looking statements are
herein qualified by reference to the cautionary statements set
forth above.
CORPORATE CONTACT
Molly Cogan
Sr. Director, Global
Communications & Government
Affairs
mcogan@nrxpharma.com
INVESTOR RELATIONS
Suzanne Messere
Investor
Relations
suzanne.messere@sternir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-leaders-to-present-at-the-hc-wainwright--co-24th-annual-global-investment-conference-301620084.html
SOURCE NRx Pharmaceuticals, Inc.